Lupin in spotlight after US subsidiary launches a generic antidepressent drug in US

Lupin's US subsidiary Lupin Pharmaceuticals, Inc. has launched a generic antidepressant medicine in the United States (US). Lupin's Duloxetine 40 mg delayed-release (DR) capsule is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength in the US. The annual market size of the branded and generic versions of antidepressant Cymbalta 20 mg, 30 mg and 60 mg capsule strengths is approximately $1.05 billion in the US, as per IMS MAT June 2015 data. Lupin made the announcement after market hours yesterday, 3 September 2015.

Wipro announced after market hours yesterday, 3 September 2015, that the company has been chosen by London-based Chelsea Football Club as its official digital and IT partner. As one of the world's leading sports brands, Chelsea Football Club will work with Wipro to create experiences for millions of its fans that span not only the in-stadium, game-day experience but also their digital experience, anytime and anywhere, Wipro and Chelsea said in a joint statement.

Glenmark Pharmaceuticals announced after market hours yesterday, 3 September 2015, that its wholly owned Swiss subsidiary, Glenmark Pharmaceuticals S.A., announced that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonistof OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival.

Glenmark has now completed clinical Phase I studies for GBR 830 in the Netherlands. GBR 830 was well tolerated and its safety and pharmacokinetics profile in healthy volunteers fully support the transition into clinical Phase 2 studies. Preparations for initiating Phase 2 studies in both atopic dermatitis and celiac disease in the US and Europe are well advanced. Glenmark expects dosing to commence in the next few months. These are indications with an unmet medical need and in addition also offer the possibility to characterize the mode of action of GBR 830 in detail in these patient populations, the company said in a statement. GBR 830 targets activated T cells. This cell type drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease, the company said.

National Buildings Construction Corporation (NBCC) announced after market hours yesterday, 3 September 2015, that it secured total business amounting Rs 386.78 crore (approximately) from various clients in the month of August 2015.

Powered by Capital Market - Live News